

Express Mail Label No. EL728728447US

Date of Deposit: February 28, 2001

PATENT

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Sedivy et al.

U.S. Serial No.: 09/654,281

Filed: 09/01/2000

Entitled: Kinase Inhibitors and Methods of Use
in Screening Assays and Modulation
of Cell Proliferation and Growth


Attorney Docket No.: 3564/1010

RECEIVED

MAR 13 2001

Group: 1642 TECH CENTER 1600/2900

Examiner: Tran, M



BOX SEQUENCE

Commissioner for Patents and Trademarks
Washington, D.C. 20231

**AMENDMENT AND RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID
SEQUENCE DISCLOSURES**

Sir:

The following is submitted in response to the Notice to Comply With Requirements For Patent Applications Containing Nucleotide And/Or Amino Acid Sequence Disclosures mailed by the PTO on February 7, 2001.

In the Specification:

Please make the following amendments to the specification to incorporate SEQ ID Nos for the sequence listing submitted herewith.

1. On page 8, line 21, after "TLX₃DPD(Z)PX₃(B)X₄EX₂HX_nYX₄PX₍₂₄)GXHR(O)VXZX₃Q", please insert --(SEQ ID NO: 1)--.

2. On page 23, line 4, after "necessary for RKIP activity.", please insert --(Human PEBP (SEQ ID NO:2); Murine PEBP (SEQ ID NO:3); Drosophila (SEQ ID NO:4); C. Elegans

B/

Attorney Docket No.: 3564/1010
USSN: 09/654,2811
Filed: 9/1/00
Page 2 of 2




BL
concluded
(SEQ ID NO: 5); Antirrhinum-CEN (SEQ ID NO:6); Aradopsis-TFL1 (SEQ ID NO:7); Yeast
(SEQ ID NO: 8))--.

3. On page 32, line 1, after "TLX₃DPD(Z)PX₃(B)X₄EX₂H_YX₄PX₍₂₋
₄₎GXHR(O)VXZX₃Q", please insert --(SEQ ID NO:1)--.
4. On page 33, line 3, after "CACCGCTATGTCTGGCTGGTTACGAGCAG-3",
please insert --(SEQ ID NO:9)--.
5. On page 44, line 21, after "TGA(C/G)TCA", please insert --(SEQ ID NO:10)--.
6. On page 45, line 6, after "GGGGACTTCC", please insert --(SEQ ID NO:11)--.

Applicants, in compliance with 37 C.F.R. 1.821(f), hereby state that the information recorded in computer readable form submitted herewith is identical to the written sequence listing. Applicants, in compliance with 37 C.F.R. 1.821(g), further state that the amendments add no new matter.

Respectfully submitted,

Date: 2/28/01


Kathleen M. Williams
Reg. No. 34,380
PALMER AND DODGE, LLP
One Beacon Street
Boston, MA 02108
(617) 573-0451